Navigation Links
PARI Pharma's Nebulized DSCG Shows Results Similar to Inhaled Steroids in Asthma Studies Presented at ATS
Date:5/20/2009

chamber.

The study compared various lung function parameters, such as forced expiratory volume in 1 sec (FEV1), forced vital capacity (FVC), mean expiratory flow (MEF 50% pred), inflammatory markers, such as serum percent Eosinophils and expired nitric oxide (FeNo), asthma symptom scores, required beta agonist use, and cortisol levels. The mean asthma symptom score decreased significantly in both treatment groups over the 6 month treatment period from 5.2 +/- 2.5 to 3.07 +/- 2.2 (p=0.021) for the ICS cohort and from 5.6 +/- 1.5 to 3.2 +/- 1.9 (p <0.001) for the IsoCrom group, respectively. No significant change in lung function was observed during the six-month treatment with either inhaled corticosteroids or IsoCrom.

PARI's Comparative in-vitro assessment of IsoCrom & a novel 6% DSCG formulation

Sophisticated aerodynamic droplet and particle size assessments in a cascade impactor operated at different humidity levels revealed how delivery and deposition performance of aerosols can be affected. In-vitro breath simulation tests mimicking breathing patterns of 3 and 10 year old children demonstrated drug delivery performance is nearly unaffected when electronic eFlow Technology nebulizers were used for inhalation. The novel 6% DSCG solution may also offer new therapeutic perspectives due to the combined anti-asthmatic and antiviral potency of DSCG.

"Since the relevance of mast cells in lung vascular remodeling and the development of pulmonary hypertension was also demonstrated in an ATS paper by researchers from Canada, Finland and Germany, nebulized DSCG may also be explored as a new therapeutic for the treatment of pulmonary hypertension," stated Dr. Wolfgang M. Kuebler, professor of vascular physiology and pathophysiology at the Charite University Hospital, Berlin, Germany and associate professor at the Department of Surgery of the University of Toronto, Canada.


'/>"/>

SOURCE PARI Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ePharmaSolutions Clinical Trial Investigator Portal Wins Bio-IT World 2009 Best Practice Award
2. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
3. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
4. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
5. Pharmasset Reports Fiscal Year End 2008 Financial Results
6. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
7. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
8. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
9. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
10. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
11. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 4, 2015  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... of the Phase II proof of concept clinical ... as a monotherapy in the treatment of chronic ... highly significant and clinically meaningful improvement from baseline ... measured on a 100mm unit Visual Analog Scale ...
(Date:3/4/2015)... 2015  The strongest driver of demand in ... elderly population, according to Kalorama Information. The finding ... healthcare market research publisher, Global Orthopedic Device ... factors such as obesity is contributing to the ... product designs and the trend toward cost effective ...
(Date:3/4/2015)... China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or ... in China, today announced its financial results for the ... Fourth Quarter 2014 Financial Highlights , Total ... 36.2%, or 36.8% excluding the impact of foreign currency ... in the same quarter of 2013. , Gross ...
Breaking Medicine Technology:Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 2Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 3Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 4Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 5Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 6Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 7Kalorama: Growing Elderly Population Drives Orthopedic Device Market 2Kalorama: Growing Elderly Population Drives Orthopedic Device Market 3China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 2China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 3China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 4China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 5China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 6China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 7China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 8China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 9China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 10China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 11China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 12China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 13China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 14China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 15China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 16China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 17China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 18China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 19China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 20China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 21China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 22
... N.J., Sept. 28, 2011 Findings from an international Phase ... showed the device was safe and effective at restoring continence ... with a colostomy.  In addition, 87% of users rated the ... "very good," according to the study results published in the ...
... Edwards, Inc. (Nasdaq: MSHL ), an oncology ... targeting cancer metabolism, announced today that it has entered ... Limited, to sell common stock in a private placement ... and expenses of the offering, through the sale of ...
Cached Medicine Technology:Vitala™ Pouchless Continence Control Device Shown to be Safe and Effective for up to 12 Hours in Phase 3 Clinical Trial 2Vitala™ Pouchless Continence Control Device Shown to be Safe and Effective for up to 12 Hours in Phase 3 Clinical Trial 3Marshall Edwards Announces $2 Million Private Placement 2Marshall Edwards Announces $2 Million Private Placement 3
(Date:3/4/2015)... New York, New York (PRWEB) March 04, 2015 ... ( http://www.lipitorlawsuitcenter.com/ ) that allege the statin drug caused ... forward in the U.S. District Court, District of South ... Conference will be convened on March 26, 2015 at ... have been directed to submit a Joint Status report ...
(Date:3/4/2015)... WV (PRWEB) March 04, 2015 TROY ... (TSPE) software, which provides the ultimate level of security ... at the Hilton Houston Plaza Medical Center located at ... , Beginning at 7 AM, TROY Healthcare Solutions ... TROY Healthcare Solutions will offer brief presentations each hour ...
(Date:3/4/2015)... FDA’s New Inspection Approach:, What Your Inspector ... 2015 — 1:30 p.m. – 3:00 p.m. EDT, ... hours of an inspection whether a manufacturer’s in trouble ... list, they’ll merely ask for reassurance that they know ... “bad” list, the manufacturer must get ready to convince ...
(Date:3/4/2015)... March 04, 2015 Cook For Your ... that teaches healthy cooking to people touched by cancer, ... Lodge. The program, run by founder Ann Ogden, will ... Sport Management. The unique partnership will expand the program ... founded CFYL in 2007. After going through her own ...
(Date:3/4/2015)... 2015 The ability of volumetric ... assessment and help improve breast cancer risk prediction ... for presentation at the European Congress of Radiology ... - eight posters and 2 session presentations - ... density and quantitative breast imaging software tools to ...
Breaking Medicine News(10 mins):Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 2Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 3Health News:TROY Healthcare to Offer Prescription Solutions that can save a Hospital $100,000 2Health News:TROY Healthcare to Offer Prescription Solutions that can save a Hospital $100,000 3Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 2Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 3Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 4Health News:Drexel University and Cook for Your Life Team Up 2Health News:Drexel University and Cook for Your Life Team Up 3Health News:Drexel University and Cook for Your Life Team Up 4Health News:Drexel University and Cook for Your Life Team Up 5Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 2Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 3Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 4Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 5
... care plans share some important elements, but Sen. ... result in higher overall health care,spending than Sen. ... health policy researcher., Thorpe, professor of health ... Health, is the author of two analyses that ...
... least one disability, CDC says , , THURSDAY, Oct. 2 (HealthDay ... five people -- have some type of disability, according to ... a new CDC study finds that black, Hispanic and Native ... disproportionately higher rates than white or Asian Americans. , Overall, ...
... to Address Critical Issues During ... National Breast Cancer Awareness Month, DALLAS, Oct. 2 ... debate between vice presidential candidates Sen. Joe,Biden and Gov. Sarah ... Ifill reserve time for an issue that is both timely ...
... to Receive Full Benefits After Retirement, WASHINGTON, ... employer-sponsored retirement plans, retiree,medical plans or other financial ... Security or Medicare payments after they retire. Confidence ... female or have a,lower level of education, according ...
... Pa., Oct. 2 InnerLink, an innovative,developer of health ... company in Central Pennsylvania by the Central Penn Business,Journal. ... honors,businesses that have made significant contributions to the growth,strength, ... are honored to be recognized for our recent growth," ...
... AIDS in an unfiltered way that is both public ... this exploration may lead to another way to distribute ... associate professor of information sciences and technology (IST), an ... blog following an August 2006 ABC News story, "Out ...
Cached Medicine News:Health News:Emory Health Policy Expert Weighs in on Candidates' Health Care Plans 2Health News:Emory Health Policy Expert Weighs in on Candidates' Health Care Plans 3Health News:Minorities With Disabilities Report Poorer Health 2Health News:Susan G. Komen for the Cure(R) Advocacy Alliance Suggests Questions for Vice Presidential Debate 2Health News:Older Workers Worried About Promised Medicare and Social Security Benefits, Watson Wyatt Survey Finds 2Health News:Older Workers Worried About Promised Medicare and Social Security Benefits, Watson Wyatt Survey Finds 3Health News:InnerLink Named Among Fastest Growing Companies in Central Pennsylvania 2Health News:African-American blogs offer key health communications tool 2Health News:African-American blogs offer key health communications tool 3
... Utilizing process automation, robust interfaces ... EMR/Practice Management), and rules-based technology, ... improves efficiency, reduces errors, and ... Harvest LIS includes many powerful, ...
... The Bio-Optics LSM-12000 is a new ... powerful new tool in anterior segment diagnostics ... easy to operate, easy to maintain, and ... is the only High Magnification Slit-Lamp Biomicroscope ...
... 28 Hue test studies the characteristic ... Farnsworth D15, however this 28 hue ... of sensitivity. Case comes with a ... readable. Kit includes laminated scoring template ...
This is a reduced form of the 100 Hue test and L'Anthony New Color Test. The 40 Hue test is obviously quicker to administer. It provides extensive chromatic sensitivity and gives a quantitative score...
Medicine Products: